{"filing":{"accession_number":"0001140361-26-032951","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-12","primary_document":"ef20080199_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126032951/ef20080199_8k.htm"},"events":[{"id":27770,"run_id":25344,"accession_number":"0001140361-26-032951","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses the completion status of a material acquisition: Vertex Pharmaceuticals' merger with Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. The disclosure reports that HSR Act waiting period expired on August 12, 2026, antitrust approvals in Austria, Germany, and Australia have been received (subject to final Australian waiting period expiration on August 27, 2026), and closing is expected in early September 2026 following shareholder approval on August 28, 2026. This represents a change of control transaction that is material to investors.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29438,"accession_number":"0001140361-26-032951","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion status of a material acquisition: Vertex Pharmaceuticals' merger with Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. The disclosure reports that HSR Act waiting period expired on August 12, 2026, antitrust approvals in Austria, Germany, and Australia have been received (subject to final Australian waiting period expiration on August 27, 2026), and closing is expected in early September 2026 following shareholder approval on August 28, 2026. This represents a change of control transaction that is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:33:39.326837+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29438,"accession_number":"0001140361-26-032951","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion status of a material acquisition: Vertex Pharmaceuticals' merger with Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. The disclosure reports that HSR Act waiting period expired on August 12, 2026, antitrust approvals in Austria, Germany, and Australia have been received (subject to final Australian waiting period expiration on August 27, 2026), and closing is expected in early September 2026 following shareholder approval on August 28, 2026. This represents a change of control transaction that is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:33:39.326837+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-14"}]}